Antonio Álvarez-Cienfuegos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonio Álvarez-Cienfuegos has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- José Alberto García
Infectious Diseases Unit, Hospital General Universitario de Elche and Universidad Miguel Hernández de Elche , Alicante
4 shared publications L. Cantero-Nieto
Department of Emergency, Hospital Santa Ana, Granada, Spain
4 shared publications- María Paz Martínez-Vidal
Division of Rheumatology, Hospital San Juan de Alacant , Alicante
4 shared publications - Norberto Ortego-Centeno
Unidad de Enfermedades Sistémicas, Hospital San Cecilio, Granada, España
4 shared publications - José Raúl Noguera-Pons
Rheumatology Section, Hospital General Universitario de Elche, Elche, Spain
3 shared publications Lucia Cantero-Nieto
Department of Emergency, Hospital Santa Ana, Granada, Spain
3 shared publications
Latest Publications
- 15 January 2024
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 20 (1) , 8-13
Osteoporosis in psoriatic arthritis: Risk factors, insufficiency fractures and its association with the disease activity
- 15 January 2024
- Published by Elsevier in Reumatología Clínica (English Edition)
- Vol. 20 (1) , 8-13
Osteoporosis in psoriatic arthritis: Risk factors, insufficiency fractures and its association with the disease activity
- 26 June 2023
- Published by Elsevier in Reumatología Clínica
- Vol. 20 (1) , 8-13
Osteoporosis in psoriatic arthritis: Risk factors, insufficiency fractures and its association with the disease activity
- 26 June 2023
- Published by Elsevier in Reumatología Clínica
- Vol. 20 (1) , 8-13
Osteoporosis in psoriatic arthritis: Risk factors, insufficiency fractures and its association with the disease activity
- 1 July 2021
- Published by Elsevier in Revista Colombiana de Reumatología (English Edition)
- Vol. 28 (3) , 197-202
Use of benzodiazepines and antidepressants in patients who attend a Rheumatology clinic
- 1 July 2021
- Published by Elsevier in Revista Colombiana de Reumatología (English Edition)
- Vol. 28 (3) , 197-202
Use of benzodiazepines and antidepressants in patients who attend a Rheumatology clinic
- 1 July 2021
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 24 (3) , 362-368
Association Between FGF-23 Levels and Risk of Fracture in Women With Systemic Sclerosis
- 1 July 2021
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 24 (3) , 362-368
Association Between FGF-23 Levels and Risk of Fracture in Women With Systemic Sclerosis
- Open Access
- 31 March 2021
- Published by Philippine College of Physicians
- Vol. 59 (1) , 9-13
Fibroblast Growth Factor-23 is associated with High-density lipoprotein in Systemic sclerosis Female patients
Introduction: Fibroblast growth factor-23 (FGF23) is a circulating regulator of phosphate and vitamin D metabolism and has been implicated as a putative pathogenic factor in cardiovascular disease. The objectives of this study were: to compare serum FGF23 levels between systemic sclerosis (SSc) patients and healthy controls and to investigate possible associations between FGF23 and serum lipid profile in SSc patients. Methods: This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. We enrolled 62 consecutive female patients affected by SSc and 62 healthy women who served as controls. Cardiovascular risk factors and related biochemical parameters were collected. Serum FGF23 was analyzed using enzyme-linked immunosorbent assay (ELISA). Linear regression was used to examine the cross-sectional associations of serum FGF23 concentrations with high density lipoprotein-cholesterol (HDL-c). Results: There was no significant differences in FGF23 levels between the patients and controls (78.2 ± 60.5 vs. 80.3 ± 56.3 pg/mL, p= 0.662), but we found a statistically significant inverse relationship between FGF23 and HDL-c measurements (r= -0.27; p= 0.03) in women with SSc. In addition, in the linear regression model, higher FGF23 concentrations were associated with lower HDL-c [β = -1.45 95% CI (-2.81, -0.08); p < 0.05]. Conclusions: We report an association between circulating FGF23 and HDL-c in SSc female patients, representing a novel pathway linking high FGF23 to an increased cardiovascular risk. Keywords: Fibroblast growth factor-23, High-density lipoprotein, Systemic sclerosis.
- 31 March 2021
- Published by Philippine College of Physicians
- Vol. 59 (1) , 9-13
Open AccessFibroblast Growth Factor-23 is associated with High-density lipoprotein in Systemic sclerosis Female patients
Introduction: Fibroblast growth factor-23 (FGF23) is a circulating regulator of phosphate and vitamin D metabolism and has been implicated as a putative pathogenic factor in cardiovascular disease. The objectives of this study were: to compare serum FGF23 levels between systemic sclerosis (SSc) patients and healthy controls and to investigate possible associations between FGF23 and serum lipid profile in SSc patients. Methods: This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. We enrolled 62 consecutive female patients affected by SSc and 62 healthy women who served as controls. Cardiovascular risk factors and related biochemical parameters were collected. Serum FGF23 was analyzed using enzyme-linked immunosorbent assay (ELISA). Linear regression was used to examine the cross-sectional associations of serum FGF23 concentrations with high density lipoprotein-cholesterol (HDL-c). Results: There was no significant differences in FGF23 levels between the patients and controls (78.2 ± 60.5 vs. 80.3 ± 56.3 pg/mL, p= 0.662), but we found a statistically significant inverse relationship between FGF23 and HDL-c measurements (r= -0.27; p= 0.03) in women with SSc. In addition, in the linear regression model, higher FGF23 concentrations were associated with lower HDL-c [β = -1.45 95% CI (-2.81, -0.08); p < 0.05]. Conclusions: We report an association between circulating FGF23 and HDL-c in SSc female patients, representing a novel pathway linking high FGF23 to an increased cardiovascular risk. Keywords: Fibroblast growth factor-23, High-density lipoprotein, Systemic sclerosis.
- 1 October 2020
- Vol. 45 (4) , 259-264
Role of fibroblast growth factor-23 in calcinosis in women with systemic sclerosis
Objective: Systemic sclerosis (SSc) is a complex disorder of unknown etiology. The purpose of this study was to evaluate fibroblast growth factor-23 (FGF-23) serum levels in women with SSc compared with healthy controls and to examine a possible association between FGF-23 serum levels with the presence of calcinosis in SSc patients. Methods: This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. Sixty-two women with SSc and 62 age and sex matched healthy controls were included in this study. FGF-23 serum concentration was evaluated by indirect enzyme-linked immunosorbent assay (ELISA). Results: There was no significant difference in FGF-23 levels between SSc patients and healthy controls (78.2 +/- 60.5 vs. 80.3 +/- 56.3 pg/mL, p= 0.662). Regarding the characteristics of the disease, we found a relationship between the values of FGF-23 and the presence of calcinosis. The levels of FGF-23 are higher in patients suffering from calcinosis (p= 0.028). Conclusion: We observed the presence of higher levels of serum FGF-23 in SSc female patients with calcinosis. Therefore, FGF-23 could be a possible therapeutic target for future treatments.
- 1 October 2020
- Vol. 45 (4) , 259-264
Role of fibroblast growth factor-23 in calcinosis in women with systemic sclerosis
Objective: Systemic sclerosis (SSc) is a complex disorder of unknown etiology. The purpose of this study was to evaluate fibroblast growth factor-23 (FGF-23) serum levels in women with SSc compared with healthy controls and to examine a possible association between FGF-23 serum levels with the presence of calcinosis in SSc patients. Methods: This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. Sixty-two women with SSc and 62 age and sex matched healthy controls were included in this study. FGF-23 serum concentration was evaluated by indirect enzyme-linked immunosorbent assay (ELISA). Results: There was no significant difference in FGF-23 levels between SSc patients and healthy controls (78.2 +/- 60.5 vs. 80.3 +/- 56.3 pg/mL, p= 0.662). Regarding the characteristics of the disease, we found a relationship between the values of FGF-23 and the presence of calcinosis. The levels of FGF-23 are higher in patients suffering from calcinosis (p= 0.028). Conclusion: We observed the presence of higher levels of serum FGF-23 in SSc female patients with calcinosis. Therefore, FGF-23 could be a possible therapeutic target for future treatments.
- 1 October 2020
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 23 (4) , 561-567
Association Between Homocysteine Serum Level and Bone Mineral Density in Patients With Rheumatoid Arthritis
- 1 October 2020
- Published by Elsevier in Journal of Clinical Densitometry
- Vol. 23 (4) , 561-567
Association Between Homocysteine Serum Level and Bone Mineral Density in Patients With Rheumatoid Arthritis
- 26 August 2020
- Vol. 38 Suppl 1 (3) , 92-97
Association between homocysteine levels and arterial stiffness in women with systemic sclerosis.
The purpose of this study was to evaluate homocysteine (Hcy) serum levels in women with systemic sclerosis (SSc) compared with healthy controls and to examine possible associations between Hcy and markers of arterial stiffness. A cross-sectional study was performed at a single hospital between November 2017 and May 2019: 62 women with SSc and 62 age- and sex-matched healthy controls were enrolled. Pulse wave velocity (PWV) was measured non-invasively along the carotid-femoral arterial segment. Serum Hcy was analysed using immunonephelo-metric method. There was a significant difference in Hcy serum levels between SSc female patients and healthy controls (11.9±3.3 vs. 10.3±2.3 μmol/ml, p=0.002). Serum levels of Hcy were positively correlated with PWV (r=0.28, p<0.05), brain natriuretic peptide (BNP) (r=0.36, p<0.05) and disease duration (r=0.38, p<0.05), within the SSc group. In addition, in the linear regression model, higher Hcy concentrations were associated with higher PWV [β=0.74 95% CI (0.085, 1.394); p=0.027], BNP [β=0.04 95% CI (0.014, 0.072); p=0.004] and disease duration [β=0.18 95% CI (0.070, 0.300); p=0.002]. In multiple linear regression model adjusting for covariants, Hcy remained positively related to the PWV [β=0.033 95% CI (0.003, 0.062); p=0.031]. Our findings revealed a positive correlation between Hcy serum levels and PWV, which indicates that high levels of Hcy may predispose to the development of vascular stiffness in patients with SSc.
- 26 August 2020
- Vol. 38 Suppl 1 (3) , 92-97
Association between homocysteine levels and arterial stiffness in women with systemic sclerosis.
The purpose of this study was to evaluate homocysteine (Hcy) serum levels in women with systemic sclerosis (SSc) compared with healthy controls and to examine possible associations between Hcy and markers of arterial stiffness. A cross-sectional study was performed at a single hospital between November 2017 and May 2019: 62 women with SSc and 62 age- and sex-matched healthy controls were enrolled. Pulse wave velocity (PWV) was measured non-invasively along the carotid-femoral arterial segment. Serum Hcy was analysed using immunonephelo-metric method. There was a significant difference in Hcy serum levels between SSc female patients and healthy controls (11.9±3.3 vs. 10.3±2.3 μmol/ml, p=0.002). Serum levels of Hcy were positively correlated with PWV (r=0.28, p<0.05), brain natriuretic peptide (BNP) (r=0.36, p<0.05) and disease duration (r=0.38, p<0.05), within the SSc group. In addition, in the linear regression model, higher Hcy concentrations were associated with higher PWV [β=0.74 95% CI (0.085, 1.394); p=0.027], BNP [β=0.04 95% CI (0.014, 0.072); p=0.004] and disease duration [β=0.18 95% CI (0.070, 0.300); p=0.002]. In multiple linear regression model adjusting for covariants, Hcy remained positively related to the PWV [β=0.033 95% CI (0.003, 0.062); p=0.031]. Our findings revealed a positive correlation between Hcy serum levels and PWV, which indicates that high levels of Hcy may predispose to the development of vascular stiffness in patients with SSc.
- 1 January 2020
- Vol. 38 (1) , 50-57
FGF23-Klotho axis in patients with rheumatoid arthritis
Objective We aimed to compare serum Klotho and fibroblast growth factor-23 ( FGF-23) levels between rheumatoid arthritis (RA) patients and healthy controls. Possible association between FGF-23 and soluble Klotho with different characteristic of the disease as well as their potential role as surrogate markers of cardiovascular disease (CVD) were studied. Methods Sixty-three patients with RA recruited at Vega-Baja Hospital, Orihuela (Spain) from November 2016 to May 2018 and sixty-five age-and sex-matched healthy controls were included in this study. Serum Klotho and FGF-23 were analysed using ELISA. Results Patients had higher serum levels of Klotho than healthy controls (p.0.0001). They were positively associated with the presence of anticitrullinated peptide antibody and rheumatic factor (p< 0.05). Klotho serum levels were higher in RA patients treated with biologic agents than in those undergoing conventional therapy (p=0.008). However, no association with carotid intima media thickness was found. Although no significant differences in serum FGF-23 levels between patients and controls were found (p=0.43), FGF-23 levels were positively associated with low-density lipoprotein (LDL-c) level (p<0.05) and smoking (p=0.008) in patients with RA. Conclusion The increased serum Klotho levels in RA patients, especially in those undergoing biologic therapy, may indicate a potential implication in the pathogenesis of the disease. Although levels of FGF-23 were related to LDL-c levels, the FGF-23-Klotho axis does not seem to be related to subclinical arteriosclerosis in RA.
- 1 January 2020
- Vol. 38 (1) , 50-57
FGF23-Klotho axis in patients with rheumatoid arthritis
Objective We aimed to compare serum Klotho and fibroblast growth factor-23 ( FGF-23) levels between rheumatoid arthritis (RA) patients and healthy controls. Possible association between FGF-23 and soluble Klotho with different characteristic of the disease as well as their potential role as surrogate markers of cardiovascular disease (CVD) were studied. Methods Sixty-three patients with RA recruited at Vega-Baja Hospital, Orihuela (Spain) from November 2016 to May 2018 and sixty-five age-and sex-matched healthy controls were included in this study. Serum Klotho and FGF-23 were analysed using ELISA. Results Patients had higher serum levels of Klotho than healthy controls (p.0.0001). They were positively associated with the presence of anticitrullinated peptide antibody and rheumatic factor (p< 0.05). Klotho serum levels were higher in RA patients treated with biologic agents than in those undergoing conventional therapy (p=0.008). However, no association with carotid intima media thickness was found. Although no significant differences in serum FGF-23 levels between patients and controls were found (p=0.43), FGF-23 levels were positively associated with low-density lipoprotein (LDL-c) level (p<0.05) and smoking (p=0.008) in patients with RA. Conclusion The increased serum Klotho levels in RA patients, especially in those undergoing biologic therapy, may indicate a potential implication in the pathogenesis of the disease. Although levels of FGF-23 were related to LDL-c levels, the FGF-23-Klotho axis does not seem to be related to subclinical arteriosclerosis in RA.